{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:53:54Z","timestamp":1790996034957,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI125859"],"award-info":[{"award-number":["AI125859"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized.\n                    <jats:italic>Segmented filamentous bacteria<\/jats:italic>\n                    (\n                    <jats:italic>SFB<\/jats:italic>\n                    ) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how\n                    <jats:italic>SFB<\/jats:italic>\n                    antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut\u2013lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-A\n                    <jats:sup>b<\/jats:sup>\n                    -restricted epitope derived from\n                    <jats:italic>SFBNYU_003340<\/jats:italic>\n                    and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate\n                    <jats:italic>SFB<\/jats:italic>\n                    antigen effects on tumor immunogenicity. We found that expression of the\n                    <jats:italic>SFB<\/jats:italic>\n                    epitope in cancer cells decreased the number of lung tumor nodules, and\n                    <jats:italic>SFB<\/jats:italic>\n                    colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8\n                    <jats:sup>+<\/jats:sup>\n                    Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly,\n                    <jats:italic>SFB<\/jats:italic>\n                    triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut\u2013lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.\n                  <\/jats:p>","DOI":"10.1007\/s00262-025-04275-x","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:33:10Z","timestamp":1766586790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity"],"prefix":"10.1007","volume":"75","author":[{"given":"Jessica Tzu-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Ngoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"4275_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS (2024) Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13216537","journal-title":"J Clin Med"},{"key":"4275_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","volume":"30","author":"YR Murciano-Goroff","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB, Wolchok JD (2020) The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 30:507\u2013519. https:\/\/doi.org\/10.1038\/s41422-020-0337-2","journal-title":"Cell Res"},{"key":"4275_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8052212","volume":"2022","author":"L Yang","year":"2022","unstructured":"Yang L, Ning Q, Tang SS (2022) Recent advances and next breakthrough in immunotherapy for cancer treatment. J Immunol Res 2022:8052212. https:\/\/doi.org\/10.1155\/2022\/8052212","journal-title":"J Immunol Res"},{"key":"4275_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S (2025) Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24:136. https:\/\/doi.org\/10.1186\/s12943-025-02305-x","journal-title":"Mol Cancer"},{"key":"4275_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun DA, Moranzoni G, Chea V et al (2025) A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639:474\u2013482. https:\/\/doi.org\/10.1038\/s41586-024-08507-5","journal-title":"Nature"},{"key":"4275_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359:1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"4275_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Yang M, Zhang D, Chen M, Zhu D (2022) Clinical cancer immunotherapy: current progress and prospects. Front Immunol 13:961805. https:\/\/doi.org\/10.3389\/fimmu.2022.961805","journal-title":"Front Immunol"},{"key":"4275_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030441","author":"WJ MacDonald","year":"2025","unstructured":"MacDonald WJ, Purcell C, Pinho-Schwermann M, Stubbs NM, Srinivasan PR, El-Deiry WS (2025) Heterogeneity in cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17030441","journal-title":"Cancers (Basel)"},{"key":"4275_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4508794","volume":"2019","author":"M Sambi","year":"2019","unstructured":"Sambi M, Bagheri L, Szewczuk MR (2019) Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J Oncol 2019:4508794. https:\/\/doi.org\/10.1155\/2019\/4508794","journal-title":"J Oncol"},{"key":"4275_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390290","volume":"43","author":"M Piper","year":"2023","unstructured":"Piper M, Kluger H, Ruppin E, Hu-Lieskovan S (2023) Immune resistance mechanisms and the road to personalized immunotherapy. Am Soc Clin Oncol Educ Book 43:e390290. https:\/\/doi.org\/10.1200\/EDBK_390290","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4275_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M (2021) Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br J Cancer 125:927\u2013938. https:\/\/doi.org\/10.1038\/s41416-021-01413-x","journal-title":"Br J Cancer"},{"key":"4275_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/EDBK_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C (2018) Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book 38:169\u2013178. https:\/\/doi.org\/10.1200\/EDBK_200643","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4275_CR13","doi-asserted-by":"publisher","first-page":"1236856","DOI":"10.3389\/fimmu.2023.1236856","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xue N, Wang Z, Zeng X, Ji N, Chen Q (2023) Targeting Th17 cells: a promising strategy to treat oral mucosal inflammatory diseases. Front Immunol 14:1236856. https:\/\/doi.org\/10.3389\/fimmu.2023.1236856","journal-title":"Front Immunol"},{"key":"4275_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cellimm.2017.10.015","volume":"322","author":"Z Asadzadeh","year":"2017","unstructured":"Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, Azizi G, Baradaran B (2017) The paradox of Th17 cell functions in tumor immunity. Cell Immunol 322:15\u201325. https:\/\/doi.org\/10.1016\/j.cellimm.2017.10.015","journal-title":"Cell Immunol"},{"key":"4275_CR15","doi-asserted-by":"publisher","first-page":"1192303","DOI":"10.3389\/fimmu.2023.1192303","volume":"14","author":"Y Pan","year":"2023","unstructured":"Pan Y, Yang W, Tang B, Wang X, Zhang Q, Li W, Li L (2023) The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment. Front Immunol 14:1192303. https:\/\/doi.org\/10.3389\/fimmu.2023.1192303","journal-title":"Front Immunol"},{"key":"4275_CR16","doi-asserted-by":"publisher","first-page":"1224269","DOI":"10.3389\/fimmu.2023.1224269","volume":"14","author":"J Xing","year":"2023","unstructured":"Xing J, Man C, Liu Y, Zhang Z, Peng H (2023) Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment. Front Immunol 14:1224269. https:\/\/doi.org\/10.3389\/fimmu.2023.1224269","journal-title":"Front Immunol"},{"key":"4275_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajpath.2012.08.041","volume":"182","author":"J Ye","year":"2013","unstructured":"Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182:10\u201320. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.041","journal-title":"Am J Pathol"},{"key":"4275_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2017.08.109","volume":"493","author":"Y Song","year":"2017","unstructured":"Song Y, Yang JM (2017) Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer. Biochem Biophys Res Commun 493:1\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2017.08.109","journal-title":"Biochem Biophys Res Commun"},{"key":"4275_CR19","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e6","volume":"20","author":"DS Kuen","year":"2020","unstructured":"Kuen DS, Kim BS, Chung Y (2020) IL-17-producing cells in tumor immunity: friends or foes? Immune Netw 20:e6. https:\/\/doi.org\/10.4110\/in.2020.20.e6","journal-title":"Immune Netw"},{"key":"4275_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","volume":"24","author":"MT Anvar","year":"2024","unstructured":"Anvar MT, Rashidan K, Arsam N et al (2024) Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies? Cancer Cell Int 24:355. https:\/\/doi.org\/10.1186\/s12935-024-03525-9","journal-title":"Cancer Cell Int"},{"key":"4275_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.625667","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L, Gonzalez-Navajas JM (2021) The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy. Front Immunol 12:625667. https:\/\/doi.org\/10.3389\/fimmu.2021.625667","journal-title":"Front Immunol"},{"key":"4275_CR22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/hep.30960","volume":"71","author":"W Qiu","year":"2020","unstructured":"Qiu W, Wang B, Gao Y et al (2020) Targeting histone deacetylase 6 reprograms interleukin-17-producing helper T cell pathogenicity and facilitates immunotherapies for hepatocellular carcinoma. Hepatology 71:1967\u20131987. https:\/\/doi.org\/10.1002\/hep.30960","journal-title":"Hepatology"},{"key":"4275_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007661","author":"Y Luo","year":"2023","unstructured":"Luo Y, Shreeder B, Jenkins JW et al (2023) Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007661","journal-title":"J Immunother Cancer"},{"key":"4275_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s41467-018-03900-x","volume":"9","author":"JF Anker","year":"2018","unstructured":"Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591. https:\/\/doi.org\/10.1038\/s41467-018-03900-x","journal-title":"Nat Commun"},{"key":"4275_CR25","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3389\/fimmu.2019.02750","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yin Y, Chen X, Zhao Y, Wu Y, Li Y, Wang X, Chen H, Xiang C (2019) Induction of intestinal Th17 cells by flagellins from segmented filamentous bacteria. Front Immunol 10:2750. https:\/\/doi.org\/10.3389\/fimmu.2019.02750","journal-title":"Front Immunol"},{"key":"4275_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nature13279","volume":"510","author":"Y Yang","year":"2014","unstructured":"Yang Y, Torchinsky MB, Gobert M et al (2014) Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510:152\u2013156. https:\/\/doi.org\/10.1038\/nature13279","journal-title":"Nature"},{"key":"4275_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","volume":"139","author":"II Ivanov","year":"2009","unstructured":"Ivanov II, Atarashi K, Manel N et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485\u2013498. https:\/\/doi.org\/10.1016\/j.cell.2009.09.033","journal-title":"Cell"},{"key":"4275_CR28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.immuni.2009.08.020","volume":"31","author":"V Gaboriau-Routhiau","year":"2009","unstructured":"Gaboriau-Routhiau V, Rakotobe S, Lecuyer E et al (2009) The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31:677\u2013689. https:\/\/doi.org\/10.1016\/j.immuni.2009.08.020","journal-title":"Immunity"},{"key":"4275_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cell.2015.08.058","volume":"163","author":"K Atarashi","year":"2015","unstructured":"Atarashi K, Tanoue T, Ando M et al (2015) Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163:367\u2013380. https:\/\/doi.org\/10.1016\/j.cell.2015.08.058","journal-title":"Cell"},{"key":"4275_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.immuni.2014.03.005","volume":"40","author":"Y Goto","year":"2014","unstructured":"Goto Y, Panea C, Nakato G, Cebula A, Lee C, Diez MG, Laufer TM, Ignatowicz L, Ivanov II (2014) Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 40:594\u2013607. https:\/\/doi.org\/10.1016\/j.immuni.2014.03.005","journal-title":"Immunity"},{"key":"4275_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/imm.12950","volume":"154","author":"KL Flannigan","year":"2018","unstructured":"Flannigan KL, Denning TL (2018) Segmented filamentous bacteria-induced immune responses: a balancing act between host protection and autoimmunity. Immunology 154:537\u2013546. https:\/\/doi.org\/10.1111\/imm.12950","journal-title":"Immunology"},{"key":"4275_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.immuni.2014.03.009","volume":"40","author":"E Lecuyer","year":"2014","unstructured":"Lecuyer E, Rakotobe S, Lengline-Garnier H et al (2014) Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. Immunity 40:608\u2013620. https:\/\/doi.org\/10.1016\/j.immuni.2014.03.009","journal-title":"Immunity"},{"key":"4275_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.chom.2017.10.007","volume":"22","author":"CP Bradley","year":"2017","unstructured":"Bradley CP, Teng F, Felix KM et al (2017) Segmented filamentous bacteria provoke lung autoimmunity by inducing gut-lung axis Th17 cells expressing dual TCRs. Cell Host Microbe 22:697-704 e4. https:\/\/doi.org\/10.1016\/j.chom.2017.10.007","journal-title":"Cell Host Microbe"},{"key":"4275_CR34","doi-asserted-by":"publisher","first-page":"1576141","DOI":"10.3389\/fimmu.2025.1576141","volume":"16","author":"F Ye","year":"2025","unstructured":"Ye F, Li L, Wang J, Yang H (2025) Advances in gut-lung axis research: clinical perspectives on pneumonia prevention and treatment. Front Immunol 16:1576141. https:\/\/doi.org\/10.3389\/fimmu.2025.1576141","journal-title":"Front Immunol"},{"key":"4275_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061650","author":"D Andreu-Sanz","year":"2023","unstructured":"Andreu-Sanz D, Kobold S (2023) Role and potential of different T helper cell subsets in adoptive cell therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15061650","journal-title":"Cancers (Basel)"},{"key":"4275_CR36","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood-2012-09-378653","volume":"121","author":"P Muranski","year":"2013","unstructured":"Muranski P, Restifo NP (2013) Essentials of Th17 cell commitment and plasticity. Blood 121:2402\u20132414. https:\/\/doi.org\/10.1182\/blood-2012-09-378653","journal-title":"Blood"},{"key":"4275_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature18848","volume":"535","author":"K Honda","year":"2016","unstructured":"Honda K, Littman DR (2016) The microbiota in adaptive immune homeostasis and disease. Nature 535:75\u201384. https:\/\/doi.org\/10.1038\/nature18848","journal-title":"Nature"},{"key":"4275_CR38","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4049\/jimmunol.1201989","volume":"190","author":"Y Yu","year":"2013","unstructured":"Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ (2013) Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol 190:1873\u20131881. https:\/\/doi.org\/10.4049\/jimmunol.1201989","journal-title":"J Immunol"},{"key":"4275_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C (2025) Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer 24:5. https:\/\/doi.org\/10.1186\/s12943-024-02208-3","journal-title":"Mol Cancer"},{"key":"4275_CR40","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jbmr.154","volume":"25","author":"L Yang","year":"2010","unstructured":"Yang L, Edwards CM, Mundy GR (2010) Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 25:1701\u20131706. https:\/\/doi.org\/10.1002\/jbmr.154","journal-title":"J Bone Miner Res"},{"key":"4275_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133501","author":"R Hatae","year":"2020","unstructured":"Hatae R, Chamoto K, Kim YH et al (2020) Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133501","journal-title":"JCI Insight"},{"key":"4275_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00276","volume":"5","author":"SR Bailey","year":"2014","unstructured":"Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM (2014) Th17 cells in cancer: the ultimate identity crisis. Front Immunol 5:276. https:\/\/doi.org\/10.3389\/fimmu.2014.00276","journal-title":"Front Immunol"},{"key":"4275_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212613120","volume":"120","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Wang Y, Gao Y et al (2023) The PRAK-NRF2 axis promotes the differentiation of Th17 cells by mediating the redox homeostasis and glycolysis. Proc Natl Acad Sci U S A 120:e2212613120. https:\/\/doi.org\/10.1073\/pnas.2212613120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"575\u201391","key":"4275_CR44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.041","volume":"161","author":"Y Lu","year":"2021","unstructured":"Lu Y, Li Y, Liu Q et al (2021) MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment. Gastroenterology 161(575\u201391):e16. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.041","journal-title":"Gastroenterology"},{"key":"4275_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.intimp.2018.01.026","volume":"56","author":"K Ma","year":"2018","unstructured":"Ma K, Yang L, Shen R, Kong B, Chen W, Liang J, Tang G, Zhang B (2018) Th17 cells regulate the production of CXCL1 in breast cancer. Int Immunopharmacol 56:320\u2013329. https:\/\/doi.org\/10.1016\/j.intimp.2018.01.026","journal-title":"Int Immunopharmacol"},{"key":"4275_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.intimp.2018.04.013","volume":"59","author":"M Ma","year":"2018","unstructured":"Ma M, Huang W, Kong D (2018) IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3. Int Immunopharmacol 59:148\u2013156. https:\/\/doi.org\/10.1016\/j.intimp.2018.04.013","journal-title":"Int Immunopharmacol"},{"key":"4275_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12026-021-09211-6","volume":"69","author":"Y Qianmei","year":"2021","unstructured":"Qianmei Y, Zehong S, Guang W, Hui L, Lian G (2021) Recent advances in the role of Th17\/Treg cells in tumor immunity and tumor therapy. Immunol Res 69:398\u2013414. https:\/\/doi.org\/10.1007\/s12026-021-09211-6","journal-title":"Immunol Res"},{"key":"4275_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","volume":"112","author":"P Muranski","year":"2008","unstructured":"Muranski P, Boni A, Antony PA et al (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112:362\u2013373. https:\/\/doi.org\/10.1182\/blood-2007-11-120998","journal-title":"Blood"},{"key":"4275_CR49","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1158\/0008-5472.CAN-16-0309","volume":"76","author":"CH Johnson","year":"2016","unstructured":"Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G (2016) Metabolite and microbiome interplay in cancer immunotherapy. Cancer Res 76:6146\u20136152. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0309","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04275-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04275-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:33:11Z","timestamp":1766586791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04275-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4275"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04275-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the Ohio State University and adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"28"}}